{"schema_version":"secwatch.filing_event.v1","accession":"0001178670-25-000008","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.095688+00:00","generated_at":"2026-05-28T02:49:36.959125+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alnylam reports preliminary FY2024 net product revenues of $1.65B (+33% YoY); guides FY2025 $2.05-2.25B","bullets":["Q4 2024 net product revenues ~$451M; FY2024 ~$1,646M, representing 33% annual growth.","2025 combined net product revenue guidance of $2.05B-$2.25B, 31% growth at mid-point vs 2024.","TTR franchise (ONPATTRO/AMVUTTRA): FY2024 ~$1,223M; 2025 guidance $1.6B-$1.725B (36% growth).","Rare franchise (GIVLAARI/OXLUMO): FY2024 ~$423M; 2025 guidance $450M-$525M (15% growth).","Company expects 2025 non-GAAP operating income profitability; vutrisiran PDUFA date March 23, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001178670-25-000008","json":"https://secwatch.observer/filing/0001178670-25-000008.json","markdown":"https://secwatch.observer/filing/0001178670-25-000008.md","text":"https://secwatch.observer/filing/0001178670-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/0001178670-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/alny-20250112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:49:36.959125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}